Prescient Therapeutics Limited (ASX:PTX) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of fully paid ordinary shares Closed: A$1.2M raised · A$0.065 a share Use of proceeds: Strengthen cash position and fund continued development of PTX-100 beyond the first Dose Optimisation Committee review | Sep 29, 2026 | US$845,261 |
| Share purchase plan of shares Closed: A$4.8M raised · A$0.065 a share Use of proceeds: Strengthen cash position and fund continued development of PTX-100 beyond the first Dose Optimisation Committee review | Sep 23, 2026 | US$3.38M |
| Share purchase plan of securities under the SPP Terms changed: share purchase plan | Sep 15, 2026 | |
| Share purchase plan of new fully paid ordinary shares Update: up to A$7M · A$0.065 a share · Reach Markets Pty Ltd Dealers: Reach Markets Pty Ltd (lead) Insiders: All eligible directors have participated in the SPP Use of proceeds: Advance PTX-100 beyond the Dose Optimisation Committee meeting expected in December 2026 | Sep 14, 2026 | US$5.04M |